Ovid Therapeutics (OVID) Stock Price, News & Analysis

Company Overview

Ovid Therapeutics is a clinical-stage biopharmaceutical company focused on the development of therapies for rare neurological disorders. Founded in 2014 and headquartered in New York, the company applies a precision medicine approach to target underlying mechanisms of disease in patients with genetic conditions affecting the central nervous system. Its research platform centers on small-molecule modulators of neurotransmitter pathways to restore neural network function in disorders with high unmet medical need.

The company’s lead development candidate, OV101 (gaboxadol), is a selective extrasynaptic GABAA receptor agonist being investigated for the treatment of Angelman syndrome and Fragile X syndrome. OV101 has demonstrated proof-of-concept activity in early clinical studies, and ongoing trials aim to further characterize its safety and efficacy profiles. In parallel, Ovid is advancing OV935, a small-molecule inhibitor targeting specific kinase pathways implicated in CDKL5 deficiency disorder, a severe form of early-onset epilepsy.

To support its global development strategy, Ovid has established strategic collaborations with industry partners. A notable agreement grants regional rights for OV935 to a leading pharmaceutical company for select Asian markets. The company maintains additional research partnerships to broaden its preclinical pipeline and leverage external expertise in rare disease biology and regulatory science.

Ovid Therapeutics completed its initial public offering on the Nasdaq market in 2018 and continues to engage with regulatory authorities to advance its clinical programs toward potential approval. The organization is led by a management team with deep experience in neuroscience drug discovery and development, supported by a board of directors comprised of seasoned professionals in biopharma innovation and commercialization.

Key Stats

• Today's Range: $2.71 to $2.83
• 50-Day Range: $2.22 to $2.93
• 52-Week Range: $0.94 to $3.11
• Volume: 1.33 million shs
• Average Volume: 1.47 million shs
• Market Capitalization: $546.84 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $5.71
• Consensus Rating: Moderate Buy

Ovid Therapeutics Stock Analysis - MarketRank™

Ovid Therapeutics scored higher than 46% of companies evaluated by MarketBeat, and ranked 549th out of 915 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.0 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Ovid Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.89, and is based on 1 strong buy rating, 7 buy ratings, no hold ratings, and 1 sell rating.

Upside Potential

Ovid Therapeutics has a consensus price target of $5.71, representing about 104.1% upside from its current price of $2.80.

Amount of Analyst Coverage

Ovid Therapeutics has only been the subject of 3 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: N/A

Earnings Growth

Earnings for Ovid Therapeutics are expected to remain at ($0.40) per share in the coming year.

Price to Earnings Ratio vs. the Market

The P/E ratio of Ovid Therapeutics is -9.03, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Ovid Therapeutics is -9.03, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Ovid Therapeutics has a P/B Ratio of 2.80. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

12.37% of the float of Ovid Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Ovid Therapeutics has a short interest ratio ("days to cover") of 14.01, which indicates bearish sentiment.

Change versus previous month

Short interest in Ovid Therapeutics has recently decreased by 2.62%, indicating that investor sentiment is improving.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Ovid Therapeutics does not currently pay a dividend.

Dividend Growth

Ovid Therapeutics does not have a long track record of dividend growth.

News and Social Media

• Score: 3.1 / 5
• News Sentiment: 0.94

News Sentiment

Ovid Therapeutics has a news sentiment score of 0.94. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.65 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 2 news articles for Ovid Therapeutics this week, compared to 3 articles on an average week.

MarketBeat Follows

4 people have added Ovid Therapeutics to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 1.0 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Ovid Therapeutics insiders have not sold or bought any company stock.

Percentage Held by Insiders

7.00% of the stock of Ovid Therapeutics is held by insiders.

Percentage Held by Institutions

72.24% of the stock of Ovid Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 8/13/2026
• Today: 8/23/2026
• Next Earnings (Estimated): 11/11/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Pharmaceuticals
• Sub-Industry: Pharmaceuticals
• Current Symbol: NASDAQ:OVID
• CIK: 1636651
• Web: www.ovidrx.com
• Phone: (646) 661-7661
• Fax: N/A
• Employees: 60
• Year Founded: 2014

Price Target and Rating

• Average Price Target for Ovid Therapeutics: $5.71
• High Price Target: $9.00
• Low Price Target: $4.00
• Potential Upside/Downside: +104.1%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.89
• Research Coverage: 9 Analysts

Profitability

• EPS (Trailing Twelve Months): ($0.31)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$17.41 million
• Net Margins: -240.11%
• Pretax Margin: -2,178.90%
• Return on Equity: -23.64%
• Return on Assets: -20.52%

Debt

• Debt-to-Equity Ratio: 0.05
• Current Ratio: 12.39
• Quick Ratio: 12.39

Sales & Book Value

• Annual Sales: $7.25 million
• Price / Sales: 75.43
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $1.00 per share
• Price / Book: 2.80

Miscellaneous

• Outstanding Shares: 195,300,000
• Free Float: 181,627,000
• Market Cap: $546.84 million
• Optionable: Optionable
• Beta: 0.21